Table 2 Correlation between RCC2 expression and clinicopathological features in ovarian cancer
Variables | Number | RCC2 expression | P value | |||
|---|---|---|---|---|---|---|
Low expression (−~+) | High expression (++~+++) | |||||
Age | ||||||
≤ 45 | 83 | 47 | (56.6%) | 36 | (43.4%) | 0.000a |
> 45 | 117 | 31 | (26.5%) | 86 | (73.5%) | |
Type | ||||||
Normal | 23 | 22 | (95.7%) | 1 | (4.3%) | 0.000b |
Malignant | 141 | 49 | (34.8%) | 92 | (65.2%) | |
Metastasis | 36 | 7 | (19.4%) | 29 | (80.6%) | |
Tissue | ||||||
Ovarian | 141 | 49 | (34.8%) | 92 | (65.2%) | 0.078a |
Othersc | 36 | 7 | (19.4%) | 29 | (80.6%) | |
Pathology | ||||||
Normal | 23 | 22 | (95.7%) | 1 | (4.3%) | 0.000b |
Serous | 69 | 8 | (11.6%) | 61 | (88.4%) | |
Mucinous | 46 | 35 | (76.1%) | 11 | (23.9%) | |
Serous papillary | 36 | 6 | (16.7%) | 30 | (83.3%) | |
Mucinous papillary | 23 | 7 | (30.4%) | 16 | (69.6%) | |
Grade | ||||||
1 | 59 | 33 | (55.9%) | 26 | (44.1%) | 0.000b |
2 | 58 | 11 | (19.0%) | 47 | (81.0%) | |
3 | 42 | 1 | (2.4%) | 41 | (97.6%) | |
TNM stage | ||||||
T | ||||||
1 | 70 | 29 | (41.4%) | 41 | (58.6%) | 0.031a |
2–4 | 63 | 15 | (23.8%) | 48 | (76.2%) | |
N | ||||||
0 | 60 | 22 | (36.7%) | 38 | (63.3%) | 0.542a |
1 | 36 | 11 | (30.6%) | 25 | (69.4%) | |
M | ||||||
0 | 123 | 43 | (35.0%) | 80 | (65.0%) | 0.707b |
1 | 12 | 3 | (25.0%) | 9 | (75.0%) | |